Business Context and Reporting Period
Company: Anchiano Therapeutics Ltd. (Note: Request metadata referenced "Chemomab Therapeutics Ltd.", but the filing text identifies the registrant as Anchiano Therapeutics Ltd.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter 2019
Filing Date: November 21, 2019
Context: The company filed its Q3 2019 financial results in anticipation of a significant shareholder filing a quarterly report with the Israel Securities Authority. Israeli law mandates the inclusion of these statements due to the shareholder's significant position in Anchiano.
Key Financial Metrics
The filing text serves as a cover letter and does not contain specific numerical data. The actual Financial Statements are attached as Exhibit 99.1 and incorporated by reference. Consequently, the following metrics are not provided in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt
- Liquidity
Material Changes
The filing text does not provide comparative data or discuss material changes versus the prior comparable period. Investors must refer to Exhibit 99.1 for this analysis.
Guidance, Outlook, and Risks
The text contains no management commentary, forward-looking guidance, specific risk factors, contingencies, or unusual items. The sole purpose of this specific Form 6-K is to transmit the attached financial statements to the SEC.
Investor Verification Checklist
- Verify the correct registrant name is Anchiano Therapeutics Ltd., not Chemomab Therapeutics Ltd.
- Locate and review Exhibit 99.1 (Financial Statements) for actual Q3 2019 financial data.
- Confirm the identity of the "significant shareholder" triggering the Israeli regulatory requirement.
- Check for any subsequent filings that may provide updated financial performance or operational milestones.